Canada Markets closed

AIM ImmunoTech Inc. (AIM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.9900+0.0500 (+5.32%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.9400
Open0.9776
Bid0.9702 x 1200
Ask1.0200 x 39400
Day's Range0.9601 - 1.0500
52 Week Range0.5500 - 2.4000
Volume431,389
Avg. Volume546,306
Market Cap47.37M
Beta (5Y Monthly)-0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.3780
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.83
  • GlobeNewswire

    AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

    OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26,

  • GlobeNewswire

    AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program

    AIM Chief Medical Officer David Strayer, MD AIM Chief Medical Officer David Strayer, MD Charles Lapp, MD, Principal Investigator for AMP-511 at Hunter-Hopkins Center in Charlotte, N.C. Charles Lapp, MD, Principal Investigator for AMP-511 at Hunter-Hopkins Center in Charlotte, N.C. Oved Amitay, President and CEO of the advocacy organization Solve M.E. Oved Amitay, President and CEO of the advocacy organization Solve M.E. AIM CEO Thomas K. Equels AIM CEO Thomas K. Equels OCALA, Fla., May 18, 2022

  • GlobeNewswire

    AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

    - First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical potential with checkpoint inhibitors - On track to commence Phase 2 study for lead program of Ampligen for pancreatic cancer Q3 2022 - Focus on further advancement of oncology pipeline and well-positio